Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
May 16, 2022 09:21 ET
|
Aprea Therapeutics
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
March 15, 2022 16:15 ET
|
Aprea Therapeutics
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
January 06, 2022 08:00 ET
|
Aprea Therapeutics
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
December 14, 2021 08:00 ET
|
Aprea Therapeutics
BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH...
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
December 13, 2021 08:00 ET
|
Aprea Therapeutics
60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Aprea...
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
December 09, 2021 08:00 ET
|
Aprea Therapeutics
BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
November 08, 2021 16:15 ET
|
Aprea Therapeutics
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting
November 04, 2021 16:15 ET
|
Aprea Therapeutics
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
September 20, 2021 16:15 ET
|
Aprea Therapeutics
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
September 14, 2021 08:00 ET
|
Aprea Therapeutics
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...